- Home
- YMAB vs ELDN Comparison
YMAB vs ELDN Comparison
Compare YMAB & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- ELDN
- Stock Information
- Founded
- YMAB 2015
- ELDN 2004
- Country
- YMAB United States
- ELDN United States
- Employees
- YMAB N/A
- ELDN N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- YMAB Health Care
- ELDN Health Care
- Exchange
- YMAB Nasdaq
- ELDN Nasdaq
- Market Cap
- YMAB 218.4M
- ELDN 178.4M
- IPO Year
- YMAB 2018
- ELDN N/A
- Fundamental
- Price
- YMAB $4.04
- ELDN $3.17
- Analyst Decision
- YMAB Buy
- ELDN Strong Buy
- Analyst Count
- YMAB 11
- ELDN 1
- Target Price
- YMAB $18.73
- ELDN $16.00
- AVG Volume (30 Days)
- YMAB 204.4K
- ELDN 150.4K
- Earning Date
- YMAB 05-13-2025
- ELDN 05-20-2025
- Dividend Yield
- YMAB N/A
- ELDN N/A
- EPS Growth
- YMAB N/A
- ELDN N/A
- EPS
- YMAB N/A
- ELDN N/A
- Revenue
- YMAB $87,685,000.00
- ELDN N/A
- Revenue This Year
- YMAB N/A
- ELDN N/A
- Revenue Next Year
- YMAB $18.83
- ELDN N/A
- P/E Ratio
- YMAB N/A
- ELDN N/A
- Revenue Growth
- YMAB 3.38
- ELDN N/A
- 52 Week Low
- YMAB $3.84
- ELDN $2.00
- 52 Week High
- YMAB $17.47
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- YMAB 42.87
- ELDN 48.82
- Support Level
- YMAB $4.02
- ELDN $2.85
- Resistance Level
- YMAB $4.60
- ELDN $3.51
- Average True Range (ATR)
- YMAB 0.32
- ELDN 0.25
- MACD
- YMAB -0.01
- ELDN 0.01
- Stochastic Oscillator
- YMAB 23.93
- ELDN 45.07
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.